Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mitsugu SUGIYAMA"'
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 33:540-546
Autor:
Isao Yamamoto, Noriyuki Suzuki, Mitsugu Sugiyama, Satoshi Fujii, Hiromichi Hosoda, Gakuji Gondo, N. Takagi, Yuji Yamanaka
Publikováno v:
Surgery for Cerebral Stroke. 28:248-253
Publikováno v:
Applied Entomology and Zoology. 34:231-234
Publikováno v:
Applied Entomology and Zoology. 33:375-378
Autor:
Akira Tsuburaya, Mitsunobu Kikuchi, Toshiro Yamamoto, Mitsugu Sugiyama, Noriyuki Kamiya, Yasuhisa Mochizuki
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 59:1332-1335
Publikováno v:
Applied Entomology and Zoology. 31:547-550
Publikováno v:
Applied optics. 20(19)
Measuring the reflectance variation DeltaR under dc magnetic field at Ar(+) 0.5017-microm laser line for both corpuscle and plasma human blood samples and applying statistical processing to a 2-D display of DeltaR, we can obtain useful information on
Autor:
Yasushi Onuma, Renzo Okamoto, Shinji Takita, Tomihisa Koshino, Toshitaka Takagi, Mitsugu Sugiyama, Shigeharu Negami
Publikováno v:
Nihon Kyukyu Igakukai Zasshi. 6:183-185
Autor:
Daisuke Hanashi, Yuki Ara, Kenji Okuda, Eri Hagiwara, Yohei Miyagi, Mitsugu Sugiyama, Norihisa Ishii, Takuji Yoshida, Tomoyuki Saito, Hidechika Okada, Toshitaka Takagi, Tumihisa Koshino, Susumu Kawamoto
Publikováno v:
Immunology. 103(1)
In the present study, the adjuvant effect of zymosan on human immunodeficiency virus type-1 (HIV-1)-specific DNA vaccine and the mechanism of this enhancement were studied in a murine model. We coinoculated zymosan with our candidate HIV-1 specific D
Autor:
Eri Hagiwara, Mitsuru Sugiyama, Masanosuke Nishizaki, Kenji Hamajima, Mitsugu Sugiyama, Ke-Qin Xin, Etsunosuke Noda, Hiroki Bukawa, Susumu Kawamoto, Kenji Okuda, Hidenori Kato
Publikováno v:
Vaccine. 18(13)
An effective vaccine for human immunodeficiency virus (HIV) is needed to stimulate the immune response of the genital mucus to prevent mucosal transmission of the virus. We have developed a macromolecular multicomponent peptide vaccine candidate, VC1